News
Study shows CHLOE AI’s role in advancing reproductive health research
Researchers can use Fairtility’s AI tool to further their understanding of embryo and oocyte development

Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced the highlights of a new study published in Nature’s Scientific Reports.
The study, focused on blastocyst morphometric parameters’ impact on implantation potential, highlights how Fairtility’s transparent AI decision support technology, CHLOE, can support academic research in the field of assisted reproductive technologies.
The study, entitled An artificial intelligence algorithm for automated blastocyst morphometric parameters demonstrates a positive association with implantation potential, was led by Professor Iris Har Vardi, director of Fertility and IVF Lab at Soroka University Medical Center and senior lecturer at Ben Gurion University in the Faculty of Health Sciences. Har Vardi also serves as a scientific advisor to Fairtility.

Automatic measurements of blastocyst morphometrics. (a) A day-5 blastocyst with trophectoderm (TE) and inner cell mass (ICM) cells. (b) The same embryo with markings. Blue represents the hand drawn segmentation around the outer part of the TE cells, excluding the area occupied by the zona pellucida. Green represents the ellipse that best fits around the segmented ICM pixels in the least-squares sense. Red represents the diameter of the embryo.
The study included 608 transferred blastocysts that were selected using morphokinetics and Gardner criteria. Retrospectively, researchers deployed CHLOE to automatically assess four morphometric parameters: blastocyst size, inner cell mass (ICM) size, ICM-to-blastocyst size ratio and ICM shape.
Researchers found that blastocyst size had a significant positive association with implantation such that with every 1 μm increase in blastocyst size, there was a relative increase in the odds of implantation by 2.1 per cent.
Applying CHLOE to assess these parameters retrospectively, was possible due to CHLOE’s advanced, consistent and automated assessment.
These capabilities enable researchers to study various events, biomarkers, timing and ratios objectively that were previously not possible, providing new insights for treatment decisions and opening up tremendous opportunity for more research to advance the field.
“CHLOE’s AI algorithms enabled us to measure various embryo components automatically with higher accuracy and speed than us, the embryologists,” explained Professor Har Vardi.
“As a researcher and a clinical embryologist, AI provides a powerful new tool and opens endless possibilities to further explore basic science and clinical parameters.

Professor Iris Har Vardi, director of Fertility and IVF Lab at Soroka University Medical Center and senior lecturer at Ben Gurion University
“This research highlights the potential for enhanced blastocyst selection in the IVF process using AI technology, which offers great promise for improving the effectiveness and personalisation of reproductive healthcare.”
Researchers can utilise CHLOE to further their understanding of embryo and oocyte development that may enhance current workflows, protocols and practice of reproductive health care.
Eran Eshed, co-founder and CEO of Fairtility, said: “Our mission at Fairtility is to advance and improve reproductive care through CHLOE, our AI powered software platform.
“We promote this in clinical settings through our product offerings and in academic settings to advance the science and understanding of reproductive health.
“We can leverage AI technologies to elevate care in clinics, and ensure researchers continue to advance our understanding to improve patient care in the long term.”
CHLOE is currently being used in tens of clinics around the world. Clinicians utilise CHLOE EQ for automated embryo quality assessment in IVF, CHLOE OQ to support oocyte assessment for fertility preservation, egg donation and in IVF decision making, and CHLOE KPI for clinical and operational performance monitoring.

News
Cultural stigma is a barrier to menopause help, black women say

Cultural stigma and a lack of education are making it harder to get menopause help, ethnic minority women in Jersey have said.
The women came together to share their stories at an event in St Helier hosted by Eve Studios and Liberty Underwear.
Participants were encouraged to speak openly about the symptoms they had experienced.
Angela Mowanga, from Jersey, told ITV Channel: “I became dismissive about signs and symptoms. From our parents and our grandparents, they just carried on.
“I hardly heard the word menopause spoken about in my household. We never had things like hot flushes, itchy skin and tiredness.
“So for us to start talking about menopause, there is a taboo around it. A taboo that comes from ignorance but also not being willing to educate ourselves.
“We as women of colour, societies of colour, we have a lot of taboo subjects, which now have to be highlighted with the generation today.
“However, with the modern day, society is changing. And we hope programmes like this can actually be well received.”
Daisy Ayebale, from Jersey, added: “I think it’s important we are listened to. We need the right information from the experts, but we have also been overlooked when it comes to the healthcare system.
“We need to know this information before it’s too late, before you’re gambling with your health. We are glad to be changing the narrative, we are glad to be changing things right now. We are very hopeful.”
Research shows that black women are more likely to experience menopausal symptoms earlier, more intensely and for longer.
Entrepreneur
TidalSense raises £14m to expand five-minute COPD test across NHS

Cambridge health tech company TidalSense has secured £14.2m in funding led by Cross-Border Impact Ventures to expand its AI-powered lung disease test across the NHS and into Europe and the US.
The investment, which also includes returning backers BGF, Airstream Capital and Foresight Group, will fund the rollout of a handheld diagnostic device that can detect chronic obstructive pulmonary disease (COPD) in as little as five minutes.
It will also support the development of software to diagnose asthma using the same platform.
Donna Parr is managing partner at Cross-Border Impact Ventures.
She said: We look for technology that doesn’t just have a compelling story, but a body of clinical evidence behind it.
“TidalSense has both, with a CEO who has lived the problem she’s solving, and a product that’s already live within the NHS healthcare environment, saving time for patients who have waited years for an answer.
“It is also technology that can improve access to appropriate treatment for COPD sufferers on a global basis and especially for women who are often misdiagnosed.
“This is exactly the kind of impact we want to make with our investments.”
COPD, a progressive condition that restricts airflow and makes breathing increasingly difficult, is the third leading cause of death in England, according to the NHS.
It is responsible for about 30,000 deaths each year and costs the health service an estimated £1.9bn annually.
The company believes its technology could transform how respiratory disease is diagnosed by replacing the need for conventional spirometry in many settings.
Patients simply breathe normally into the handheld device for 75 seconds while artificial intelligence analyses the breath in real time.
A diagnosis is then displayed on screen, allowing clinicians to complete the entire process in around five minutes.
TidalSense says the technology allows clinicians to assess as many as six patients an hour, compared with roughly one an hour using spirometry, which has remained the standard diagnostic test for COPD despite changing little since it was first developed in the 19th century.
Spirometry requires patients to perform forceful breathing manoeuvres and typically needs specialist staff to administer.
TidalSense chief executive Ameera Patel said: “Our ambition is really bold and broad, and it is to have a really significant impact at a population level on chronic respiratory diseases like COPD and asthma.
“We want the test to be available to anyone the first time they present with symptoms, so there’s no bias in accessibility based on where you live, your socio-economic status or your ethnicity.”
Founded in 2013 by chief engineering officer Julian Carter, who holds a PhD in microelectronics and has more than 35 years’ experience developing medical devices, TidalSense has spent more than a decade building the technology.
Its AI models have been trained on more than 2.5 million recorded breaths to identify the distinctive patterns associated with COPD.
The device was introduced into the NHS last year and is now being used by public health providers in Suffolk, north-east Essex, Wales, Glasgow and community lung screening clinics across the south of England.
Pregnancy
Women should not be pressured into an ‘ideal birth’, says health secretary

Women should not feel pressured into an “ideal birth”, health secretary Yvette Cooper has said as she promised major maternity reform.
Cooper has returned to the Department of Health and Social Care 27 years after serving as public health minister under Tony Blair.
She said maternity and child health would be a major focus of her new role, alongside significant reforms to social care.
In an interview with the Guardian, Cooper said the changes should address any pressure on women to pursue a particular birth experience.
Families affected by maternity failures have repeatedly raised concerns that some units were reluctant to escalate medical interventions because of a preference for more natural births.
Cooper said: “I would worry about any mum feeling pressurised that there is somehow a kind of an ideal birth experience to live up to when it’s always different in every case, and you have to follow the evidence, you have to have informed choice.”
As one of her first actions as health secretary, Cooper said she intended to reintroduce binding national maternity standards.
The standards were dismantled during early Conservative NHS reforms and replaced with fragmented arrangements managed separately by individual hospital trusts.
A new maternity taskforce will draft the standards, which will have five central aims.
These include ending regional differences in levels of care and tackling racial inequalities linked to poorer outcomes in deprived areas, particularly for Black and Asian women.
Patient experiences will also form part of how standards are measured, while new targets will aim to identify underperformance before a major scandal develops.
Cooper, who became the first minister to take maternity leave while serving as a junior health minister in the early 2000s, said reports into maternity scandals had been “traumatic” to read and showed that systemic change was needed.
She said: “We’ve always said the NHS is about the cradle to the grave. I want to make it a personal crusade to put the cradle back at the heart of the NHS, and to have much more focus around maternity and child health, the very beginning of a family’s life, making that much more central to the priorities of the NHS, giving it the priority that it really deserves.”
Cooper said discussions about how maternity services could better listen to mothers’ needs had been taking place for the past two decades.
However, she said the emphasis on placing women and families at the centre of care appeared to have been lost.
She said: “It feels incomprehensible that we could be in this situation in the 2020s. I went back to look at some of the things that we’d done 25 years ago.
“And what did strike me was how much we were talking then about women and families being at the centre of care and about listening to women’s views.
“It is really shocking and distressing feeling that has somehow been lost in some of the maternity units where actually it should be the central issue.
“I had a direct interest. I was pregnant at the time. But I am really struck by it now, just feeling like there is this big gap in the priorities that the NHS has been focused on.”
Cooper said she was determined to provide a robust response to Donna Ockenden’s investigations into maternity failures at Shrewsbury and Telford and Nottingham, alongside Baroness Valerie Amos’s national investigation into England’s maternity system.
The investigations highlighted systemic clinical errors, understaffing and toxic institutional cultures. They found that hundreds of infant and maternal deaths were directly linked to failures to listen to mothers and defensive attempts to protect institutions.
Amos’s review faced criticism, including the resignation of an expert adviser over the lack of explicit warnings about “normal birth ideology”.
Families also questioned whether the review’s proposed statutory maternity commissioner would have sufficient independence.
Cooper said she remained committed to introducing the role.
She said: “In the end, the most important people in the maternity services are the mothers, babies, the families. But the point of having a maternity commissioner is to make sure that those issues are championed as part of an NHS.”
She also said reforms needed to address an oppositional culture between doctors and midwives in some trusts over when medical intervention during birth may be necessary.
Cooper said: “The thing that struck me most was the sense of women feeling they weren’t being listened to … And I think that probably does go back to issues around culture.”
Cooper, who served as foreign secretary until recently, said she was prepared for a difficult period in the health role as she sought to implement Andy Burnham’s social care reforms.
She said she remained committed to establishing the national care service announced by the prime minister the previous week.
A longstanding ally of former prime minister Keir Starmer and a former rival of Burnham in the 2015 Labour leadership contest, Cooper said she believed the change of prime minister had been necessary.
She said: “Of course it’s not easy. I really did not think it was possible to win the election when I came back into the shadow cabinet in 2022. It’s only because of what Keir did that we managed to win.
“But we had very difficult local election results … we have to respond to that. But I think we’ve got a sense of energy now.
“All of the things that Andy wants to focus on and drive are also just very much the things that that people are concerned about across the country.”
Entrepreneur2 weeks agoFertility startup American Baby Company secures US$4m
News2 weeks agoFrom Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation
Fertility1 week agoNatural Cycles receives sixth FDA clearance for fertility algorithm
Wellness2 weeks agoAstraZeneca drug approved for breast cancer in EU
Wellness4 days agoCancer patient receives ‘landmark’ treatment in world-first
Sponsored Content2 weeks agoTwo opportunities for women’s health founders closing this autumn
Hormonal health2 weeks agoType 2 diabetes rising among young women, experts warn
Insight1 week agoExperimental treatment significantly slows progression of fatal brain disease in women, study finds












Pingback: Study shows CHLOE AI’s role in advancing reproductive health research - Fairtility